PAR-1拮抗剂E5555的全合成

以3-氟邻苯二酚和邻叔丁基苯酚为原料,经14步反应完全PAR-1拮抗剂--1-(3-叔丁基-5-吗啉4-甲氧基苯基)-2-(5,6-二乙氧基.7-氟-1-亚胺二氢异吲哚)乙酮氢溴酸盐(E5555)的全合成,总产率27.2%,其结构经<'1>H NMR确证.     

含多氟的4-甲基噻唑环的新型二肽基肽酶Ⅳ抑制剂的合成及其降血糖活性

设计并合成了一系列含多氟的4-甲基噻唑环的新型二肽基肽酶Ⅳ抑制剂(6a～6i),其结构经1H NMR和ESI-MS表征.以西他列汀为阳性对照药,采用小鼠体内口服葡萄糖耐受量法测试,结果显示6c和6h具有明显的降血糖作用.     

含噻唑环的二肽基肽酶Ⅳ抑制剂的设计、合成和降血糖活性研究

设计并合成了16个含噻唑环的二肽基肽酶Ⅳ(DPP-Ⅳ)抑制剂,利用IR,1H NMR,13C NMR和HR-MS表征了它们的结构.通过小鼠口服糖耐量实验测试了它们的降血糖作用,结果显示其中两个化合物具有很强的降血糖作用,一个与格列齐特相当,另一个强于格列齐特,显示了在治疗Ⅱ型糖尿病方面的前景.构效关系研究发现,这16个化合物的构效关系呈现出明显的规律.     

Synthesis and Crystal Structure of Tianagliflozin Triacetate

The title compound tianagliflozin triacetate 1 was synthesized and its crystal structure was determined by single-crystal X-ray diffraction.The crystal belongs to monoclinic system(C27H31ClO8,Mr = 518.97),space group P21 with a = 5.3913(11),b = 16.137(2),c = 15.411(3) ,β = 94.15(3)°,V = 1337.3(5) 3,Z = 2,Dc = 1.289 g/cm3,F(000) = 548,μ = 0.190 mm-1,the final R = 0.0374 and wR = 0.0809 for 3981 observed reflections(I 2σ(I)).The structure of 1,triacetate of a highly potent SGLT2 inhibitor tianagliflozin,was unambiguously determined by single-crystal X-ray diffraction,which helped to confirm the desired β configuration at the anomeric center and the position where the deoxylation occurred.The two benzene rings in the lattice are basically orthogonal to each other.There are four intermolecular hydrogen bonds in the crystal,which helps to further stabilize the crystal.     

Synthesis and Crystal Structure of 2[1-（1,1-Dimethylethyl）-5-methyl-1-H-pyrazol-4-ylcarbonyl]-N-phenyldrazinecarbothioamide

1INTRODUCTIONThiosemicarbazidespossessingNC=Sgroupareanessentialstructurefeatureresponsibleforvariousbiocidalproperties[1～7].Moreover,theyaretheconvenientandkeyintermediatesforthesyn-thesisofheterocycliccompoundssuchas1,3,4-thiadiazoles,1,2,4-triazoleand…     

Synthesis and Crystal Structure of Ethyl 5-Amino-1-[(5''-methyl-1''-t-butyl-4''-pyrazolyl)carbonyl]-3- methylthio-1H-pyrazole-4-carboxylate

The title compound, ethyl 5-amino-1-[(5'-methyl-1'-t-butyl-4'-pyrazolyl)carbonyl] -3-methylthio-1H-pyrazole-4-carboxylate 5, has been synthesized by the treatment of 4 with ethyl 2-cyano-3,3-dimethylthioacrylate, and its crystal structure was determined by X-ray diffraction method. The crystal belongs to monoclinic, space group P21/c with a = 12.194(4), b = 12.909(4), c = 11.607(4) (A), β= 90.183(5)°, V = 1827.2(10) (A)3, Mr = 365.45, Z = 4, Dc = 1.328 g/cm3, μ = 0.203 mm-1, F(000) = 776, R = 0.0586 and wR = 0.1558. Preliminary bioassays indicated that the title compound shows fungicidal and plant growth regulation activities.     

Synthesis and Crystal Structure of 2（1-Phenyl-3-methyl-5-chloro-1H-pyrazol-4-yl）-3-（1-naphthoylamido）-4-thiazolidinone

1INTRODUCTIONManypyrazolederivativeshavebeenreportedtoshowvariousbiologicalactivitiestobeusedasbactericide[1],fungicide[2],herbicide[3],insecticide[4]andvirucide[5]agents.Inaddition,4-thiazolidinoneplaysavitalroleowingtoitswiderangeofbiologi-calactivities…     

SGLT2抑制剂3-脱氧达格列净简便的汇聚式合成方法

3-脱氧达格列净(1)是一个高选择性的强效钠依赖性葡萄糖转运子2(SGLT2)抑制剂.本研究发现了一条以廉价的α-D-甲基吡喃葡萄糖(2)为起始原料的简便的3-脱氧达格列净(1)的汇聚式合成路线,共13步,总产率38%.在此过程中系统研究了4,6-O-苄叉-α-D-甲基吡喃葡萄糖苷(3)中2-OH和3-OH的选择性保护策略,使用NOE(nuclear overhauser effect)技术对区域异构体进行了结构鉴定,并对区域异构体的相对比例和相对极性提出了合理解释;在此过程中对4,6-O-苄叉-2-O-叔丁基二苯基硅基-α-D-甲基吡喃葡萄糖(4)中葡萄糖片段上位阻较大3-OH的脱氧策略也进行了系统研究,最终获得了最优的脱氧策略.该路线为一条汇聚式路线,具有廉价、操作简便的特点,可以作为一种高效合成3-脱氧苯基C-葡萄糖苷类化合物的通用方法.     

SGLT2抑制剂——3-羰基达格列净的合成新方法

以4-甲氧基苯基-β-D-吡喃葡萄糖苷为原料,经9步反应制得新型关键中间体2,4,6-三-O-苄基-3-羰基-D-葡萄糖酸内酯乙二硫醇缩酮（10）; 10与5-溴-2-氯-4′-乙氧基二苯甲烷经亲核加成反应制得甲基糖苷（12）; 12在BF₃·Et₂O催化下经Et₃SiH还原、AlCl₃脱去苄基、再经PhI(CF₃CO₂)₂氧化脱除乙二硫醇保护基合成了SGLT2抑制剂3-羰基达格列净,共13步反应,总收率9%,该合成路线包含了11个新化合物的合成,其结构经¹H NMR, ¹³C NMR, IR和HR-ESI-MS表征。     

苯萘基糖苷类化合物的合成及其治疗糖尿病的活性

以1,2-二甲氧基苯,丁二酸酐以及α-溴代四乙酰基吡喃糖为原料,设计并合成了作为SGLT2抑制剂的两个结构新颖的苯萘基糖苷化合物(6a和6b),其结构经1H NMR, 13C NMR, IR和ESI-MS确认.利用小鼠体内葡萄糖耐受量法测定了6治疗糖尿病的活性,结果发现6a具有明显的降血糖作用,其活性与阳性对照药格列齐特相当.